InMed Pharmaceuticals: The Clinical-Stage Company Setting Sites On Dominating Rare Cannabinoid Production And Commercialization Across Global Markets

Shane Johnson, SVP and General Manager of Baymedica of InMed Pharmaceuticals (NASDAQ: INM), was a guest speaker at Benzinga’s All Access on June 17th, 2022. 

InMed Pharmaceuticals is an emerging global leader in the development, manufacturing and commercialization of rare cannabinoids and health and wellness consumer products. 

Watch the full interview here

Feature photo